ConductScience.org, home

Paper · 36545708

Cited by131

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 166 citations.

PMIDTitleJournalYearIn PapersSource
42967027Enhanced Efficacy of Thalidomide-Based Cocktail With Transarterial Chemoembolization in the Management of Unresectable Hepatocellular Carcinoma: A Multi-Center Cohort Study.MedComm (2020)2026https://conductscience.org/library/papers/42967027PubMed
42958661Xiaoyao San enhances the sensitivity of hepatocellular carcinoma to 5-fluorouracilautophagy modulation.J Tradit Chin Med2026https://conductscience.org/library/papers/42958661PubMed
42927357Advances in the LI-RADS Treatment Response Algorithm: Imaging Principles, Diagnostic Challenges, and Clinical Integration Following the LI-RADS 2024 Update.Cancer Manag Res2026https://conductscience.org/library/papers/42927357PubMed
42893081Construction of a Nomogram Integrating Magnetic Resonance Imaging Features and Ephrin-A3 Expression to Predict Postoperative Overall Survival in Hepatocellular Carcinoma.J Hepatocell Carcinoma2026https://conductscience.org/library/papers/42893081PubMed
42724514Akkermansia muciniphila attenuates apatinib resistance in hepatocellular carcinoma through NF-κB-mediated reprogramming of tumor-associated macrophages.Transl Cancer Res2026https://conductscience.org/library/papers/42724514PubMed
42592511A gradient core-shell microsphere to enable effective embolization of liver cancer via interventional therapy.Regen Biomater2026https://conductscience.org/library/papers/42592511PubMed
42588737The Controlling Nutritional Status Score as a Predictive Factor for Lung Metastasis in Patients with Hepatocellular Carcinoma After Hepatectomy.Cancers (Basel)2026https://conductscience.org/library/papers/42588737PubMed
42564342Prediction of early treatment response to drug-eluting beads chemoembolization for hepatocellular carcinoma using machine learning.Front Pharmacol2026https://conductscience.org/library/papers/42564342PubMed
42542804HAIC combined with lenvatinib and tislelizumab for HCC with concurrent PVTT and pulmonary metastasis: a multicenter propensity score matching analysis.Ther Adv Med Oncol2026https://conductscience.org/library/papers/42542804PubMed
42540626Apatinib resistance mediated by IRF9 nuclear translocation in head and neck squamous cell carcinoma.iScience2026https://conductscience.org/library/papers/42540626PubMed
42445440The evolving landscape of early diagnosis for hepatocellular carcinoma: a bibliometric analysis of global research trends (2016-2026) based on WoSCC database.Transl Cancer Res2026https://conductscience.org/library/papers/42445440PubMed
42440203Huachansu triggers mitochondrial apoptosis and ER stress to inhibit hepatocellular carcinoma progression.Saudi Pharm J2026https://conductscience.org/library/papers/42440203PubMed
42433265Real-World Efficacy and Safety of TACE Combined with Lenvatinib and PD-1 Inhibitor in Conversion Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE007): A Multicenter Retrospective Study.Liver Cancer2026https://conductscience.org/library/papers/42433265PubMed
42373443[Transitional and clinical practice pathways for whole-course management of hepatocellular carcinoma in the infectious diseases department].Zhonghua Gan Zang Bing Za Zhi2026https://conductscience.org/library/papers/42373443PubMed
42358545AAT score based on pretreatment indicators predicts outcomes in unresectable HCC patients treated with TACE, Sintilimab, and Bevacizumab.Front Oncol2026https://conductscience.org/library/papers/42358545PubMed
42326932Cost-effectiveness analysis of Atezolizumab plus bevacizumab vs. Rivoceranib plus Camrelizumab as first-line treatment for unresectable hepatocellular carcinoma.Front Public Health2026https://conductscience.org/library/papers/42326932PubMed
42304258MRI radiomics and 90Y PET dosimetry for predicting hepatocellular carcinoma response after radioembolization.BMC Cancer2026https://conductscience.org/library/papers/42304258PubMed
42301580TACE plus donafenib and immune checkpoint inhibitors for intermediate HCC (CHANCE2410 study): a propensity score matching analysis.Eur Radiol Exp2026https://conductscience.org/library/papers/42301580PubMed
42292386Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study.Front Immunol2026https://conductscience.org/library/papers/42292386PubMed
42270819Sarcopenia modifies the survival benefit of triple therapy versus TACE alone in elderly patients with unresectable hepatocellular carcinoma: A multicenter retrospective cohort study.Sci Rep2026https://conductscience.org/library/papers/42270819PubMed

papers-2026-11-12-0.1.0

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/papers/v1/36545708/cited_by